AbbVie Inc.
ABBVNYSE
$284.60
Last price · USD
- Market cap
- $504.9B
- P/E
- 120.1x
- EV / EBITDA
- 32.3x
- P/S
- 8.3x
- FCF yield
- 3.5%
- Div. yield
- 2.31%
Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.
Revenue
$61.16B
+8.6%
4Y CAGR +2.1%
Gross profit
$42.96B
+8.9%
4Y CAGR +2.6%
Operating income
$20.09B
+119.9%
4Y CAGR +2.9%
Net income
$4.23B
-1.2%
4Y CAGR -22.2%
EPS (diluted)
$2.37
-0.8%
4Y CAGR -22.1%
Free cash flow
$17.82B
-0.1%
4Y CAGR -5.1%
Revenue & net income
Fiscal 2021–2025 · USD
RevenueNet income
Valuation
At $284.60 · FY2025 fundamentals
- Market cap
- $504.9B
- Enterprise value
- $568.7B
- P/E
- 120.1x
- P/S
- 8.3x
- P/B
- —
- EV / EBITDA
- 32.3x
- EV / Sales
- 9.3x
- Earnings yield
- 0.8%
- FCF yield
- 3.5%
- Shareholder yield
- 2.5%
Profitability
Margins as a share of revenue
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Gross margin | 70.2%+1.3pp | 69.0% | |
| Operating margin | 32.8%+1.0pp | 31.9% | |
| EBITDA margin | 28.8%-13.8pp | 42.6% | |
| Net margin | 6.9%-13.6pp | 20.5% | |
| FCF margin | 29.1%-10.0pp | 39.1% |
Returns & financial health
FY2025 with 4-year trend
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Return on equity | — | 74.9% | |
| Return on invested capital | 21.3% | 19.1% | |
| Return on assets | 3.2% | 7.9% | |
| Debt / equity | — | 5.03x | |
| Net debt / EBITDA | 3.62x | 2.83x | |
| Current ratio | 0.67x | 0.79x |
Cash & equivalents
$5.23B
Total debt
$69.07B
Capital allocation
How ABBV used its cash in FY2025
- Operating cash flow
- $19.03B
- Capital expenditure
- $1.21B
- Dividends paid
- $11.66B
- Share repurchases
- $980M
- Stock-based compensation
- $955M
- Diluted shares
- 1.77B
- Share count change (4Y)
- -0.2%
Analyst estimates
Consensus for upcoming fiscal years
| Fiscal year | Revenue | Growth | EPS | Growth |
|---|---|---|---|---|
| FY2025 actual | $61.16B | $2.37 | ||
| FY2026E16 analysts | $67.64B | +10.6% | $13.93 | +487.9% |
| FY2027E15 analysts | $73.52B | +8.7% | $16.41 | +17.8% |
| FY2028E9 analysts | $79.01B | +7.5% | $17.88 | +9.0% |
About AbbVie Inc.
Healthcare · Drug Manufacturers - General
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients.
abbvie.com- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael
- Employees
- 57,000
- Headquarters
- North Chicago, IL, US
- IPO date
- 2013-01-02
AbbVie Inc. (ABBV) — frequently asked questions
Answered from the company's SEC filings
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines.
Explore the full income statement, balance sheet and cash flow statement. Not investment advice.